FindTrial
Sign In

The Clinical Value of Cerebrospinal Fluid cfDNA and the Mechanistic Role of Target Genes in the Diagnosis and Treatment of Primary Central Nervous System Lymphoma

The Clinical Value of Cerebrospinal Fluid cfDNA and the Mechanistic Role of Target Genes in the Diagnosis and Treatment of Primary Central Nervous System Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114252
Enrollment
Unknown
Registered
2025-12-09
Start date
2025-12-31
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma

Interventions

Observation group:None

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Newly diagnosed PCNSL, confirmed by histopathology, cerebrospinal fluid (CSF) flow cytometry, or CSF cytology. 2.Age > 18 years. 3.Absence of severe physical or mental illnesses.

Exclusion criteria

Exclusion criteria: 1.HIV-positive status or secondary CNS lymphoma. 2.Prior radiotherapy or targeted therapy received before baseline. 3.Failure of the sample provider to sign the informed consent form. 4.The research participant has previously participated in 2 or more clinical studies. 5.Presence of risk for iatrogenic brain herniation, including clinical manifestations of significantly elevated intracranial pressure or imaging findings suggestive of posterior fossa lesions.

Design outcomes

Primary

MeasureTime frame
Progression-Free Survival;—

Countries

China

Contacts

Public ContactMengxue Zhang

Huashan Hospital, Fudan University

12307120215@fudan.edu.cn+86 21 66895019

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026